Gregory Frost, Ph.D.Chairman & CEO

Dr. Frost serves as Chairman & CEO of EXUMA Biotechnology SEZC and has also been Managing Director of F1 BioVentures, LLC since 2015. Previously, he led the Health Sector of Intrexon Corporation, a multinational public biotechnology company, where he was responsible for expanding their oncology franchise and gene and cellular-based therapies for a number of orphan diseases. From 1999 to 2014, Dr. Frost was at Halozyme Therapeutics, a San Diego public biotechnology company he co-founded, focused on oncology biologics and medication delivery, where he served on the Board of Directors and in numerous operational roles, including Chief Scientific Officer since 2002, and CEO since 2010. He has authored multiple scientific peer-reviewed and invited articles, and is an inventor on key patents supporting a number of FDA approved biologics. Dr. Frost is a member of the American Society of Clinical Oncology, the American Association for Cancer Research and is registered to practice before the U.S. Patent and Trademark Office. Dr. Frost earned his B.A. in biochemistry and molecular biology from the University of California, Santa Cruz, his Ph.D. in the Department of Pathology at the University of California, San Francisco and postdoctoral research at the Sidney Kimmel Cancer Center. As an entrepreneur, Dr. Frost brought the founding platform technologies to Halozyme and secured the initial capital for the company. In 2012, Gregory Frost was named by Forbes as one of Americas 20 most powerful CEO’s 40 and under, and was a finalist for Ernst and Young’s Entrepreneur of the Year in San Diego. Dr. Frost additionally serves on the Board of Directors of BioCom, a member-driven organization serving the life science community of Southern California and BioAtla, LLC.